American Journal of Ophthalmology
Volume 149, Issue 2 , Pages 214-220.e3, 1 February 2010

Late Varicella-Zoster Virus Dendriform Keratitis in Patients With Histories of Herpes Zoster Ophthalmicus

  • Allen Y.H. Hu

      Affiliations

    • Ocular Inflammatory Disease Center, Jules Stein Eye Institute and the Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, California
  • ,
  • Erich C. Strauss

      Affiliations

    • Francis I. Proctor Foundation for Research in Ophthalmology and the Department of Ophthalmology, University of California, San Francisco, San Francisco, California
  • ,
  • Gary N. Holland

      Affiliations

    • Ocular Inflammatory Disease Center, Jules Stein Eye Institute and the Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, California
  • ,
  • Matilda F. Chan

      Affiliations

    • Francis I. Proctor Foundation for Research in Ophthalmology and the Department of Ophthalmology, University of California, San Francisco, San Francisco, California
  • ,
  • Fei Yu

      Affiliations

    • Ocular Inflammatory Disease Center, Jules Stein Eye Institute and the Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, California
  • ,
  • Todd P. Margolis

      Affiliations

    • Francis I. Proctor Foundation for Research in Ophthalmology and the Department of Ophthalmology, University of California, San Francisco, San Francisco, California
    • Corresponding Author InformationInquiries to Todd P. Margolis, MD, PhD, Francis I. Proctor Foundation, Medical Sciences S-310, 513 Parnassus Ave, University of California San Francisco, San Francisco, CA 94143-0412

Accepted 25 August 2009. published online 11 November 2009.

Purpose

To describe the characteristics and course of late varicella-zoster virus (VZV) dendriform keratitis in patients with histories of herpes zoster ophthalmicus (HZO); to describe responses of corneal lesions to antiviral treatment; and to investigate risk factors for recurrence.

Design

Retrospective case series.

Methods

Included were patients known to have 1 or more episodes of dendriform lesions beginning at least 2 weeks after HZO in 2 academic practices. Epithelial lesions were evaluated for the presence of VZV DNA by a polymerase chain reaction assay. Demographic, medical, and ophthalmic data were collected for each episode. Responses to treatment with antiviral medications were evaluated. Cumulative risk of recurrence was determined using Kaplan-Meier analysis; potential risk factors for recurrence (age, systemic disease, lesion characteristics, corticosteroids) were evaluated using univariate Cox proportional hazard models.

Results

We identified 20 patients (14 women; median age, 65 years) who met inclusion criteria. Dendriform lesions were pleomorphic with thickened, opaque epithelium. Seven patients had systemic diseases characterized by altered immune function. VZV DNA was identified in 15 of 16 cases tested, and all lesions responded to antiviral therapy. The 1-year incidence of first recurrence was 95.8 lesions per 100 person-years of follow-up. Patients had multiple recurrences, but risk of recurrence appeared to decrease over time. No statistically significant risk factors for recurrence were identified.

Conclusions

Late dendriform lesions associated with HZO are foci of productive VZV infection. Lesions can be treated effectively with topical or systemic antiviral agents. Patients can have multiple recurrences of dendriform lesions despite treatment.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supplemental Material available at AJO.com.

PII: S0002-9394(09)00630-8

doi:10.1016/j.ajo.2009.08.030

American Journal of Ophthalmology
Volume 149, Issue 2 , Pages 214-220.e3, 1 February 2010